 Models, Economic
"Models, Economic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Statistical models of the production, distribution, and consumption of goods and services, as well as of financial considerations. For the application of statistics to the testing and quantifying of economic theories MODELS, ECONOMETRIC is available.
| Descriptor ID |
D018803
|
| MeSH Number(s) |
E05.318.740.500.600 E05.599.835.890 N05.715.360.750.530.500 N06.850.520.830.500.600
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Models, Economic".
- Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
- Investigative Techniques [E05]
- Epidemiologic Methods [E05.318]
- Statistics as Topic [E05.318.740]
- Models, Statistical [E05.318.740.500]
- Models, Economic [E05.318.740.500.600]
- Models, Theoretical [E05.599]
- Models, Statistical [E05.599.835]
- Models, Economic [E05.599.835.890]
- Health Care [N]
- Health Care Quality, Access, and Evaluation [N05]
- Quality of Health Care [N05.715]
- Health Care Evaluation Mechanisms [N05.715.360]
- Statistics as Topic [N05.715.360.750]
- Models, Statistical [N05.715.360.750.530]
- Models, Economic [N05.715.360.750.530.500]
- Environment and Public Health [N06]
- Public Health [N06.850]
- Epidemiologic Methods [N06.850.520]
- Statistics as Topic [N06.850.520.830]
- Models, Statistical [N06.850.520.830.500]
- Models, Economic [N06.850.520.830.500.600]
Below are MeSH descriptors whose meaning is more specific than "Models, Economic".
This graph shows the total number of publications written about "Models, Economic" by people in this website by year, and whether "Models, Economic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 2 | 2 | | 2006 | 1 | 2 | 3 | | 2008 | 2 | 2 | 4 | | 2010 | 1 | 0 | 1 | | 2011 | 2 | 1 | 3 | | 2012 | 0 | 2 | 2 | | 2013 | 2 | 2 | 4 | | 2014 | 0 | 2 | 2 | | 2015 | 1 | 0 | 1 | | 2016 | 0 | 3 | 3 | | 2017 | 2 | 1 | 3 | | 2018 | 1 | 0 | 1 | | 2019 | 4 | 4 | 8 | | 2020 | 1 | 4 | 5 | | 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Models, Economic" by people in Profiles.
-
Barocas JA, Savinkina A, Adams J, Jawa R, Weinstein ZM, Samet JH, Linas BP. Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. Lancet Public Health. 2022 01; 7(1):e56-e64.
-
Chatroux IC, Hersh AR, Caughey AB. Herpes Simplex Virus Serotyping in Pregnant Women With a History of Genital Herpes and an Outbreak in the Third Trimester of Pregnancy: A Cost-Effectiveness Analysis. Obstet Gynecol. 2021 01 01; 137(1):63-71.
-
Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB. A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. Pharmacoeconomics. 2020 11; 38(11):1201-1218.
-
Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2020 Jun 19; 14(5):575-587.
-
Yang H, Hao Y, Qi CZ, Chai X, Wu EQ. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective. J Manag Care Spec Pharm. 2020 Aug; 26(8):971-980.
-
Yang H, Hao Y, Chai X, Qi CZ, Wu EQ. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective. J Med Econ. 2020 Sep; 23(9):1016-1024.
-
Synnott PG, McQueen RB, Ollendorf DA, Campbell JD, Pearson SD. The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease. J Manag Care Spec Pharm. 2020 Jun; 26(6):782-785.
-
Knapp EA, Bilal U, Dean LT, Lazo M, Celentano DD. Economic Insecurity and Deaths of Despair in US Counties. Am J Epidemiol. 2019 12 31; 188(12):2131-2139.
-
Amin AP, Spertus JA, Curtis JP, Desai N, Masoudi FA, Bach RG, McNeely C, Al-Badarin F, House JA, Kulkarni H, Rao SV. The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support. Circulation. 2020 01 28; 141(4):273-284.
-
Carlson JJ, Walton SM, Basu A, Chapman RH, Campbell JD, McQueen RB, Pearson SD, Touchette DR, Veenstra D, Whittington MD, Ollendorf DA. Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States. Pharmacoeconomics. 2019 11; 37(11):1321-1327.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|